Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells

Lili Jiang, Qin Huang, Siyang Zhang, Qingfu Zhang, Jihong Chang, Xueshan Qiu, Enhua Wang, Lili Jiang, Qin Huang, Siyang Zhang, Qingfu Zhang, Jihong Chang, Xueshan Qiu, Enhua Wang

Abstract

Background: Two mature microRNAs (miRNAs), hsa-miR-125a-3p and hsa-miR-125a-5p (collectively referred to as hsa-miR-125a-3p/5p), are derived from 3' and 5' ends of pre-miR-125a, respectively. Although impaired regulation of hsa-miR-125a-5p has been observed in some tumors, the role of this miRNA in invasion and metastasis remains unclear, and few studies have examined the function of hsa-miR-125a-3p. In order to characterize the functions of hsa-miR-125a-3p/5p in invasion and metastasis of non-small cell lung cancer (NSCLC), we investigated the relationships between hsa-miR-125a-3p/5p expression and lymph node metastasis in NSCLC tissues. We also explored the impact of expression of these miRNAs on invasive and migratory capabilities of lung cancer cells.

Methods: Expression of hsa-miR-125a-3p/5p in NSCLC tissues was explored using real-time PCR. The relationships between hsa-miR-125a-3p/5p expression and pathological stage or lymph node metastasis were assessed using the Spearman correlation test. For in vitro studies, lung cancer cells were transfected with sense and antisense 2'-O-methyl oligonucleotides for gain-of-function and loss-of-function experiments. Transwell experiments were performed to evaluate cellular migration and invasion.

Results: Expression of hsa-miR-125a-3p/5p was lower in NSCLC tissues than in adjacent normal lung tissues (LAC). Furthermore, the results from the Spearman correlation test showed a negative relationship between hsa-miR-125a-3p expression and pathological stage or lymph node metastasis and an inverse relationship between hsa-miR-125a-5p expression and pathological stage or lymph node metastasis. In vitro gain-of-function experiments indicated that hsa-miR-125a-3p and hsa-miR-125a-5p function in an opposing manner, suppressing or enhancing cell migration and invasion in A549 and SPC-A-1 cell lines, respectively. These opposing functions were further validated by suppression of hsa-miR-125a-3p and hsa-miR-125a-5p expression in loss-of-function experiments.

Conclusion: Hsa-miR-125a-3p and hsa-miR-125a-5p play distinct roles in regulation of invasive and metastatic capabilities of lung cancer cells, consistent with the opposing correlations between the expression of these miRNAs and lymph node metastasis in NSCLC. These results provide new insights into the roles of miR-125a family members in the development of NSCLC.

Figures

Figure 1
Figure 1
Relative expression of hsa-miR-125a-3p in lung cancer tissues. The relative expression of hsa-miR-125a-3p decreased in 52 NSCLCs in comparison to corresponding LACs. The data are representative of three independent experiments, and the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
Figure 2
Figure 2
Relative expression of hsa-miR-125a-5p in lung cancer tissues. The relative expression of hsa-miR-125a-5p decreased in 52 NSCLCs in comparison to corresponding LACs. The results are representative of three independent experiments, and the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
Figure 3
Figure 3
Mean levels of hsa-miR-125a-3p and hsa-miR-125a-5p in lung cancer tissues. (A) The mean level of hsa-miR-125a-3p relative expression in 52 NSCLCs. (B) The mean level of hsa-miR-125a-5p relative expression in 52 NSCLCs. The values represent the means of three replicates, and the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
Figure 4
Figure 4
Prediction of hsa-miR-125a-3p and hsa-miR-125a-5p target genes. Predictions were conducted using microrna.Org, TargetScanHuman 5.1, and MiRBase webservers. Microrna.org and MiRBase predictions are based on the miRanda algorithm, while TargetScanHuman5.1 predictions are based on the TargetScan algorithm.
Figure 5
Figure 5
Relative expression of hsa-miR-125a-3p and hsa-miR-125a-5p in different lung cancer cell lines. (A) The relative expression levels of hsa-miR-125a-3p in four lung cancer cell lines, particularly the NCI-H460 cell line, were all lower than that of the HBE cell line. (B) The relative expression levels of hsa-miR-125a-5p in four lung cancer cell lines, particularly the A459 cell line, were all lower than that of the HBE cell line. The results are representative of three independent experiments, and the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
Figure 6
Figure 6
Relative levels of hsa-miR-125a-3p and hsa-miR-125a-5p were increased by transfection with sense 2'-O-methyl oligonucleotides. (A) The relative levels of hsa-miR-125a-3p were significantly increased in the sense-3p-transfected group. (B) The relative levels of hsa-miR-125a-5p were significantly increased in the sense-5p-transfected group. The results are representative of three independent experiments, and the relative expression values were calculated using the equation RQ = 2-ΔΔCt.
Figure 7
Figure 7
Effects of gain-of-function of hsa-miR-125a-3p/5p on migration and invasion of lung cancer cells. Migration assay results showed that the number of A549 cells that migrated through the microporous membrane was significantly decreased in the sense-3p group (p < 0.001). In contrast, the number of migratory SPC-A-1 cells was significantly increased in the sense-5p group (p < 0.001, bar = 20 μm). Invasion assay results showed that the number of A549 cells that invaded through the Matrigel was significantly decreased in the sense-3p group (p < 0.001). However, the number of invasive SPC-A-1 cells significantly increased in the sense-5p group (p < 0.001, bar = 20 μm). The results are representative of three independent experiments.
Figure 8
Figure 8
Effects of loss-of-function of hsa-miR-125a-3p/5p on migration and invasion of lung cancer cells. Migration assay results showed that the number of A549 cells that migrated through the microporous membrane was significantly increased in the antisense-3p group (p < 0.001). However, the number of migratory SPC-A-1 cells was significantly decreased in the antisense-5p group (p < 0.001, bar = 20 μm). Invasion assay results showed that the number of A549 cells that invaded through the Matrigel was significantly increased in the antisense-3p group (p < 0.001). In contrast, the number of invasive SPC-A-1 cells was significantly decreased in the antisense-5p group (p < 0.001, bar = 20 μm). The results are representative of three independent experiments.

References

    1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54. doi: 10.1016/0092-8674(93)90529-Y.
    1. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415–9. doi: 10.1038/nature01957.
    1. Kong W, Zhao JJ, He L, Cheng JQ. Strategies for profiling microRNA expression. J Cell Physiol. 2009;218:22–5. doi: 10.1002/jcp.21577.
    1. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293:834–8. doi: 10.1126/science.1062961.
    1. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001;106:23–34. doi: 10.1016/S0092-8674(01)00431-7.
    1. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115:199–208. doi: 10.1016/S0092-8674(03)00759-1.
    1. Ørom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–71. doi: 10.1016/j.molcel.2008.05.001.
    1. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005;3:e85. doi: 10.1371/journal.pbio.0030085.
    1. Bartel DP. MicroRNAs genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5.
    1. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004. doi: 10.1073/pnas.0307323101.
    1. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB, Nana-Sinkam SP. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008;373:607–12. doi: 10.1016/j.bbrc.2008.06.090.
    1. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008;18:350–9. doi: 10.1038/cr.2008.24.
    1. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52. doi: 10.1038/nature06487.
    1. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs -- the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9:293–302. doi: 10.1038/nrc2619.
    1. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. A pleiotropically acting microRNA miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032–46. doi: 10.1016/j.cell.2009.03.047.
    1. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28:6773–84. doi: 10.1128/MCB.00941-08.
    1. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128–2136. doi: 10.1038/sj.onc.1210856.
    1. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol. 2008;28:5369–5380. doi: 10.1128/MCB.00479-08.
    1. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006;66:4549–4552. doi: 10.1158/0008-5472.CAN-05-3850.
    1. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98. doi: 10.1016/j.ccr.2006.01.025.
    1. Agresti Alan. A Survey of Exact Inference for Contingency Tables. Statistical Science. 1992;7:131–177. doi: 10.1214/ss/1177011454.
    1. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348–60. doi: 10.1261/rna.1034808.
    1. Séguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin InvestigDrugs. 2009;18:1505–17. doi: 10.1517/13543780903179294.
    1. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33:1290–1297. doi: 10.1093/nar/gki200.
    1. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435:839–843. doi: 10.1038/nature03677.
    1. Fabani MM, Gait MJ. miR-122 targeting with LNA/2¢-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA -peptide conjugates. RNA. 2008;14:336–346. doi: 10.1261/rna.844108.
    1. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, Chang YS, Chen SJ. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100:1002–11. doi: 10.1038/sj.bjc.6604948.
    1. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle. 2008;7:2643–6.
    1. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12. doi: 10.1016/j.ydbio.2006.08.028.
    1. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer. 2007;58:392–6. doi: 10.1016/j.lungcan.2007.07.013.
    1. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA. 2008;105:5166–71. doi: 10.1073/pnas.0800121105.
    1. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;4:1696–704. doi: 10.1373/clinchem.2007.101741.
    1. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005;102:3627–32. doi: 10.1073/pnas.0500613102.
    1. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM, Maitra A. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8:340–6.
    1. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med. 2005;11:712–714. doi: 10.1038/nm0705-712.
    1. Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer. 2008;44:2753–9. doi: 10.1016/j.ejca.2008.09.037.
    1. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–52. doi: 10.1038/nature06487.
    1. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim BiophysActa. 2009;1796:293–308.
    1. Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Cancer Res. 2009;102:67–101. full_text.
    1. Ma L, Weinberg RA. Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet. 2008;24:448–56. doi: 10.1016/j.tig.2008.06.004.
    1. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH, Dhanasekaran SM, Chinnaiyan AM, Athey BD. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res. 2009;19:1175–83. doi: 10.1101/gr.089367.108.
    1. Menten P, Saccani A, Dillen C, Wuyts A, Struyf S, Proost P, Mantovani A, Wang JM, Van Damme J. Role of the autocrine chemokines MIP-1alpha and MIP-1beta in the metastatic behavior of murine T cell lymphoma. J Leukoc Biol. 2002;72:780–9.
    1. Van Deventer HW, Wu QP, Bergstralh DT, Davis BK, O'Connor BP, Ting JP, Serody JS. C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9. Am J Pathol. 2008;173:253–64. doi: 10.2353/ajpath.2008.070732.
    1. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology. 2008;48:146–56. doi: 10.1002/hep.22297.
    1. Ferland C, Flamand N, Davoine F, Chakir J, Laviolette M. IL-16 Activates Plasminogen-Plasmin System and Promotes Human Eosinophil Migration into Extracellular Matrix via CCR3-Chemokine-Mediated Signaling and by Modulating CD4 Eosinophil Expression. J Immunol. 2004;173:4417–24.
    1. Li Y, Qiu X, Zhang S, Zhang Q, Wang E. Hypoxia induced CCR7 expression via HIF-1alpha and HIF-2alpha correlates with migration and invasion in lung cancer cells. Cancer Biol Ther. 2009;8:322–30.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다